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Abstract 
 
Objective: The objective of this selective EBM review is to 
determine whether or not the use of oral amphetamines 
reduces cocaine use in cocaine-dependent individuals. 
Study Design: Review of three English language randomized 
control trials (RCTs) published in 2001, 2003 and 2004.  
Data Sources: 3 randomized controlled trials published 
after 1999 were obtained using PubMed, OVID, and Medline.  
Outcomes Measured: The efficacy of using d-amphetamine to 
promote cocaine use cessation in cocaine-dependent 
individuals, determined using immunoassay and mass 
spectrometric analysis to identify cocaine metabolites in 
the participant’s urine. 
Results: Grabowski et al (2004) found a significant 
reduction in the use of cocaine in cocaine-dependent 
individuals, while Grabowski et al (2001) and Shearer et al 
were unable to show a significant reduction.  
Conclusion: Evidence supporting the role of oral 
amphetamines in reducing cocaine use in cocaine-dependent 
individuals is inconclusive and conflicting at this time. 
However, further research and larger scale analysis is 
warranted and feasible considering the suggestive outcomes 
these studies represent.  
Keywords: Cocaine-dependence, d-amphetamine, randomized-
controlled trial, treatment !
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Introduction 
Cocaine is a drug with increasing concern for abuse 
and dependence, with minimal available treatment options, 
that is in association with an array of psychiatric, 
medical, and individual social problems1. The drug is coined 
“the caviar of street drugs,” and given a reputation to be 
abused by celebrities, fashion models, and Wall Street 
traders2. However, addiction is a disease that does not 
discriminate, affecting individuals of all backgrounds and 
socioeconomic status. The effects of cocaine not only occur 
during the “high”, which only lasts about 15 minutes, but 
afterwards the negative effects take a toll on the heart, 
brain, and one’s emotions2. Considering the long-term damage 
consuming this drug has on the body, it is imperative to 
determine a way to help cocaine-dependent individuals 
overcome their addiction. This paper evaluates three double 
blind, randomized controlled trials determining the 
efficacy of Amphetamine (d-amphetamine) as an oral 
medication to promote cessation of cocaine use. 
There are approximately 1.6 million current users of 
cocaine in the US, with the past-year prevalence of cocaine 
dependence is estimated to be 1.1%3. With such a high rate 
of addiction, it is alarming to consider the strain it has 
on our country’s health care expenses. Although an 
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estimation of annual healthcare cost due to cocaine-
dependence is not recorded, it is included in the more than 
$484 billion dollars that substance abuse as a whole costs 
our nation per year, as reported by the National Institute 
of Drug Abuse4. Health care practitioners are exposed to a 
large number of these patients on a daily basis. 
Considering some people keep it hidden that they are 
abusing drugs, it is difficult to accurately depict. There 
is not an exact estimate available for healthcare visits 
due to cocaine-dependence; however, in 2009 NIDA reported 
an estimated 422,896 emergency room visits related to 
cocaine use5.  
Cocaine addiction/dependence is proven to be in 
association with the stimulatory effect the drug has on the 
central nervous system’s reward inducing center6. The 
sympathomimetic mechanism of action directly increases the 
activation of dopaminergic receptors, while also blocking 
the reuptake of norepinephrine and serotonin6. CNS 
stimulation from cocaine use has shown to increase harmful 
behavior in addicted individuals.  These behaviors include 
psychosis, HIV and other transmittable disease risk-taking 
through unsafe sexual practice and injecting, compulsive 
binge behavior, violence, and other antisocial behaviors6. 
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The drug effects can even change one’s personality enough 
to alter their actions.  
Stimulatory drugs, which are controlled substances, 
are the only class of medications that are showing promise 
as therapeutic agents for treatment of cocaine dependence. 
However, there is resistance in this field of research 
considering the addictive properties of these 
pharmaceutical medications6. Research and treatment are 
being conducted in other countries using other stimulant 
medications such as: Dopamine agonists, Methylphenidate, 
Modafinil, Armodafinil, and stimulant antidepressants such 
as Bupropion3. Cognitive-behavioral psychosocial therapy is 
also an adjunctive mainstay of treatment for cocaine 
dependence7. Currently there is not a drug of choice for 
promoting cessation of cocaine use in patients with 
cocaine-dependence.  The medications previously listed have 
shown minimal efficacy in controlled studies. Research 
suggests that d-amphetamine may be used as an oral 
alternative to treat patients with cocaine-dependence with 
the goal to improve the likelihood of cessation. 
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Objective 
The objective of this selective EBM review is to 
determine whether or not the use of oral amphetamines can 
reduce cocaine use in cocaine-dependent individuals. 
Methods 
 The criteria used for selection of the studies used 
were patients with cocaine-dependence who were seeking help 
in cessation of use and who were willing to participate in 
a controlled research trial. The intervention used was d-
amphetamine 30mg and 60mg daily. The treatment group 
receiving d-amphetamine was compared to the control group 
who was receiving a visually matched placebo. The outcome 
measured was the efficacy of using d-amphetamine to promote 
cocaine use cessation in cocaine-dependent individuals. 
This was determined using immunoassay and mass 
spectrometric analysis to identify cocaine metabolites in 
the participant’s urine. The types of studies included were 
3 randomized, double blind, and placebo controlled clinical 
trials. 
The data sources used are 3 randomized controlled 
trials published after 1999 that were obtained using PubMed, 
OVID, and Medline. The keywords used in searches were 
“Cocaine-dependence”, “d-amphetamine”, “randomized-
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controlled trial”, and “treatment”. All of the articles 
were written in English and published in peer-reviewed 
journals.  The articles were selected based on their 
relevance to the clinical question and if they included 
patient oriented outcomes. The inclusion criteria involved 
were studies that were randomized, controlled, and double 
blind. The participants in the trials were cocaine-
dependent, without an age requirement. The exclusion 
criteria in the RCTs were patients with medical 
comorbidities that could interfere with the study outcomes. 
All the studies utilized in this review deal with patient 
oriented outcomes (POEMS). The summary statistical analysis 
utilized in the studies reviewed included ANOVA, NNT, ABI, 
p-values, and F-score. Table 1 demonstrates the 
demographics of the participants in the study.  
Outcome Measured 
 The outcome measured was the efficacy of using d-
amphetamine to promote cocaine use cessation in cocaine-
dependent individuals. This was determined by the absence 
of cocaine metabolites in that participant’s urine. A 
urinalysis was conducted using laboratory immunoassay and 
mass spectrometry to identify benzoylecgonine, a metabolite 
of cocaine, at a cutoff of 300ng/mL. 
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Table 1: Demographics and Characteristics of included studies 
Study Type # of Pts. Age (yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria W/D Interventions 
Grabowski8 
(2004) 
Double 
blind 
RCT 
94 18-50 
Cocaine 
and heroin 
dependence 
diagnosis 
(DSM IV) 
in good 
health and 
without 
other 
psych 
diagnosis 
with 
normal 
cardiac 
function 
Other 
significant 
medical 
diagnosis  
32 
15/30mg and 
30/60mg of d-
amphetamine 
per day and 
methadone  
x 26 weeks 
Grabowski7 
(2001) 
Double 
blind 
RCT 
128 Not Specified 
Cocaine-
dependence 
diagnosis 
(DSM IV) 
in good 
medical 
health 
Other 
psychiatric 
diagnosis  
16 
15/30mg and 
30/60mg of d-
amphetamine 
x 12 weeks  
Shearer6 
(2003) 
Double 
blind 
RCT 
30 Not Specified  
Cocaine 
dependence 
diagnosis 
(DSM-IV 
criteria) 
and a 
cocaine-
positive 
urine 
sample or 
documented 
history of 
cocaine 
use 
Other 
significant 
medical 
conditions 
likely to make 
trial 
participation 
hazardous (such 
as 
cardiovascular 
conditions and 
schizophrenia). 
4 
60mg of d-
amphetamine 
per day 
x 14 weeks 
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Results 
 Three studies were included, two of which compared d-
amphetamine therapy group against placebo group in cocaine-
dependent individuals, and one that compared d-amphetamine 
therapy group against placebo group in cocaine and heroin-
dependent individuals. Two of the studies did not specify 
an age parameter, but the third study restricted it to 18 
to 50 years of age. To report conclusive data, individuals 
were presumptive for cocaine use if their benzoylecgonine 
(BZ) level was 300 ng/mL or greater on urine screening.  
 In the study by Grabowski et al (2001), three groups 
were analyzed. There was a group taking 0mg (placebo), 
15/30mg d-amphetamine, and 30/60mg d-amphetamine. The trial 
was 12 weeks in duration and included 128 individuals. The 
proportion of urine screens that were positive at intake 
was 0.80, 0.68, and 0.65, respectively, for the individuals 
designated to each group previously listed. There was a 
dose-doubling phase that occurred at month two. For the 
complete sample, differences were not significant at the 
end of the study (Pearson x2=2.257, df=2,p=0.323, N=128). 
When examining if there was a difference with dose as a 
variable, there still was no significance (F=0.147, 
df=2.99,p=0.864,N=102). However, all groups showed 
improvement. When the 16 individuals with negative urine 
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drug screen from initial screening (entry of study) who 
continued to be negative throughout the study were excluded, 
there was a difference in the pattern of cocaine use. The 
data for month 1 was similar to the complete sample, but 
differences emerged after the dose was doubled. The 60mg 
group showed fewer BZ-positive urine screens than placebo 
group during month 3 (F=4.577, df=1.9, p=0.061, N=11), but 
this data was not significant. The study reported six 
subjects that stated medication side effects as a reason 
for discontinuation of therapy. These included changes in 
their appetite and muscle twitches or movements. The study 
concludes that there was an absence of adverse effects that 
diminishes concerns for this treatment, but caution is 
essential7.  
In the study Grabowski et al (2004), three groups were 
involved in the study, 0mg, 15/30mg, and 30/60mg of d-
amphetamine. Of the 94 subjects who began the medical 
treatment, 62 remained at the end of the study. This study 
also included a dose-doubling phase at month two. Analysis 
comparing the single to doubled dose phases indicated that 
the 30/60-dose group significantly reduced cocaine use when 
compared to the other groups (Interaction F=4.34, df=2.56, 
p=0.0176; Cohen’s effect-size f=0.394). The side effects 
noted were changes in appetite, constipation, and 
Strate, Oral Amphetamine in Cocaine-Dependent 9 
drowsiness, leading to only a 2% dropout rate. The safety 
concern was of cardiovascular origin, requiring each 
subject to be evaluated by a cardiologist prior to 
initiation of therapy8.  
 In the study Shearer et al, the 30 subjects were 
cocaine and heroin-dependent and were divided into two 
groups, 0mg (placebo) or 60mg d-amphetamine. The proportion 
of positive urine samples declined in the treatment group 
from 94% at baseline to 56% and 69% during the study. The 
placebo group’s positive urine samples remained constant at 
79% throughout the study. The between-group difference at 
the final week 14 was 22.4% (x2=1.7, p=0.2), not showing 
significant difference. As calculated by the results of the 
study, for every 10 subjects treated with oral amphetamines, 
one more would discontinue cocaine use when compared to 
placebo (NNT represented in Table 2). The commonly reported 
side effects during this study were insomnia and disturbed 
sleep, however they did not differ between groups6. 
Table 2: Clinical Efficacy of Using d-amphetamine to treat Cocaine-Dependence 
Study CER (0mg) EER (60mg) ABI NNT 
Shearer et al 21% 31% 10% 10 
CER- control event rate, EER- experimental event rate, ABI- absolute benefit increase, 
NNT- number needed to treat 
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Discussion  
 Although all trials do not show significant evidence, 
they imply that d-amphetamine at higher doses (60mg) could 
be a potentially safe and effective treatment to reduce 
cocaine use in cocaine-dependent individuals. However, the 
possibility of adverse events may lead to skepticism. 
Insurance companies currently cover the cost of d-
amphetamine for most individuals for the treatment of 
attention deficit disorder. However, it has not been 
approved for this application. Considering the fact that 
this medication is CNS stimulating in nature, there is also 
potential for abuse.  
The study by Shearer et al was too small to 
confidently evaluate the efficacy of d-amphetamine in 
relation to placebo in reducing cocaine use, cravings and 
related harms6. The size of the study is a limiting factor 
in this field of research. Grabowski et al (2004) found a 
significant reduction in the use of cocaine in cocaine-
dependent individuals, while Grabowski et al (2001) and 
Shearer et al were unable to show a significant reduction.   
Furthermore, as a whole, these studies give support to 
merit future controlled studies to evaluate the utility of 
d-amphetamine in the management of cocaine dependence.  
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Conclusion 
 Evidence supporting the role of oral amphetamines in 
reducing cocaine use in cocaine-dependent individuals is 
inconclusive and conflicting at this time. Nevertheless, 
further research and larger scale analysis is warranted and 
feasible considering the suggestive outcomes these studies 
represent.  
Future studies should attempt to increase the amount 
of participants and put particular emphasis on patients 
with cocaine-dependence alone, instead of subjects with 
multiple drug dependencies. Higher dosing at 60mg daily d-
amphetamine appears to be the more promising treatment. 
Focus on comparing placebo to the higher dose in a 
controlled setting could show more profound statistical 
outcomes. Also, the duration of the studies should be 
lengthened to prove safety of this treatment for long-term 
control. Although the results of these studies are modest, 
treatment with d-amphetamine shows more promising outcomes 
than other previously researched medications in treating 
the serious problem of cocaine-dependence and abuse.  
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